Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies (SAFRAN)

18 de septiembre de 2026 actualizado por: Hospices Civils de Lyon

Type I Interferon Excess in Autoimmune Diseases and Genetic Type I Interferonopathies

Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies are characterized by chronic and excession IFN-I signaling and production contributing to disease pathogenesis. Aberrant IFN-I production can be triggered through the activation of multiple signaling pathways, particularly those involving intracellular and extracellular RNA and DNA sensing receptors.

We hypothesize that excessive IFN-I production results from an increased tonic activation state of nucleic acid sensors and/or an enhanced responsiveness of these sensors to endogenous nucleic acids, thereby sustaining pathological IFN-I signaling and chronic inflammation.

The aim of this study is to characterize the type I interferon (IFN-I) response, defined by both the IFN-I gene signature and plasma IFN-α levels, following stimulation with a panel of ligands specific for DNA- and RNA-sensing pathways.

Descripción general del estudio

Descripción detallada

The investigators hypothesize that chronic overproduction of type I interferons (IFN-I) is driven by increased basal activation of nucleic acid-sensing pathways and/or heightened cellular responsiveness to endogenous nucleic acids, leading to sustained IFN-I signaling and persistent inflammation. The objective of the study is to characterize the IFN-I response by assessing both the interferon gene signature and plasma IFN-α levels following stimulation of PBMCs with a panel of DNA- and RNA-sensing pathway-specific ligands.

The SAFRAN study protocol comprises two study visits for patients: a mandatory Visit 1 (V1) and an optional Visit 2 (V2), the performance of which depends on the results obtained at V1. Healthy control participants will undergo Visit 1 (V1) only.

During Visit 1 (V1), the investigator will perform a clinical assessment as part of routine disease management. Disease activity will be evaluated using validated clinical scoring systems. For patients with systemic lupus erythematosus (SLE), disease activity will be assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). For patients with systemic sclerosis, skin involvement will be evaluated using the modified Rodnan Skin Score (mRSS). In addition, disease activity will be assessed in all patients using the Physician Global Assessment (PGA) scale.

During Visit 2 (V2), patients in whom an abnormality in interferon signaling is identified through the in vitro assays will undergo additional blood sampling during a routine follow-up visit conducted as part of standard clinical care. An additional blood volume of 12 mL will be collected to further characterize the abnormality detected in the previous sample (V1), within 12 months of the initial assessment.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Bron, Francia, 69500
        • Hôpital Femme-Mère-Enfant
        • Contacto:
        • Investigador principal:
          • Alexandre BELOT, MD, Ph D
      • Lyon, Francia, 69003
        • Hôpital Edouard Herriot
        • Contacto:
        • Investigador principal:
          • Thomas BARBA, MD
      • Oullins, Francia, 69495
        • Centre Hospitalier Lyon-Sud
        • Contacto:
        • Investigador principal:
          • Mael RICHARD, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años a 60 años (Niño, Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Patient

  • Patient followed at the Hospices Civils de Lyon (HCL) for their disease.

  • Patient aged over 6 years and under 60 years.

  • Body weight ≥ 25 kg.

  • Patient with a confirmed diagnosis of

    • Systemic lupus erythematosus
    • Myositis, histologically confirmed or not
    • Systemic sclerosis,
    • Mixed connective tissue disease, according to the Sharp or Kasukawa criteria Undifferentiated connective tissue disease, according to the criteria proposed by Mosca et al.
    • Genetically confirmed monogenic lupus or monogenic interferonopathy.
  • Patient, parents, or legal guardians informed about the study and having signed the informed consent form.

Healthy Volunteer Participants

  • Subjects aged over 6 years and under 60 years.
  • Body weight greater than or equal to 25 kg.
  • Participants, parents, or legal guardians who have been informed about the study and have provided written informed consent.

Exclusion Criteria:

Patient

  • documented infection or symptoms consistent with a bacterial or viral infection within 2 weeks prior to sampling
  • Subjects currently participating in an interventional drug study
  • Vaccination within 1 month prior to sampling
  • Pregnant, parturient, or breastfeeding women
  • Individuals deprived of liberty by judicial or administrative decision
  • Individuals receiving psychiatric care
  • Individuals admitted to a healthcare or social care institution for reasons other than participation in the research
  • Adults subject to a legal protection measure
  • Individuals not affiliated with a social security scheme or not covered by an equivalent health insurance system

Healthy Volunteer Participants

  • Documented infection or symptoms consistent with a bacterial or viral infection occurring within 2 weeks prior to sample collection.
  • Participant with a long-term chronic disease (ALD) or any chronic medical condition.
  • Participant with a primary immunodeficiency.
  • Vaccination within 1 month prior to sample collection.
  • History of neoplasia (< 5 years) or ongoing neoplastic disease.
  • Pregnant, parturient, or breastfeeding women.
  • Individuals deprived of liberty by a judicial or administrative decision.
  • Individuals receiving psychiatric care.
  • Individuals admitted to a health or social care institution for purposes other than participation in research.
  • Adults subject to a legal protection measure (guardianship or curatorship).
  • Individuals not affiliated with a social security system or not benefiting from an equivalent health insurance scheme.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Patients

Patients with systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies

Healthy volunteers will undergo a blood draw of a total volume of 20 mL for the following analyses: ex vivo analysis of the interferon signaling pathway (12 mL) and biological sample collection, if the patient/holder of parental authority provides consent (8 mL).

Otro: control

Healthy volunteer

Healthy volunteers will undergo a blood draw of a total volume of 20 mL for the following analyses: ex vivo analysis of the interferon signaling pathway (12 mL) and biological sample collection, if the patient/holder of parental authority provides consent (8 mL).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
IFN-I signature score
Periodo de tiempo: Day 1 and Month 12 (if applicable)

The interferon signature assessed by transcriptomic analysis and IFN-α concentrations measured using the Simoa assay will be compared across the different disease groups and with healthy volunteers.

Day 1 and Month 12 (if applicable)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical phenotype
Periodo de tiempo: Day 1 and Month 12 (if applicable)

Correlation between the extent of specific organ involvement and the activation of nucleic acid-sensing pathways, assessed by the levels of IFN-α production.

Day 1 and Month 12 (if applicable)
plasma IFN-α concentration
Periodo de tiempo: Day 1 and Month 12 (if applicable)

In vitro change in the IFN signature and IFN-α production in patients' PBMCs after exposure to selective inhibitors of overactivated IFN-I signaling pathways

Day 1 and Month 12 (if applicable)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de enero de 2033

Finalización del estudio (Estimado)

1 de enero de 2033

Fechas de registro del estudio

Enviado por primera vez

10 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Publicado por primera vez (Actual)

24 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir